Pharma Equity Group A/S Cl A
PEG.CO
| Exchange: | CO |
| Currency | Danish krone |
| ISIN: | DK0061155009 |
| Primary Ticker: | PEG.CO |
| Fiscal Year End: | September |
| Sector: | Healthcare |
| Industry: | Biotechnology |
| Gic Sector: | Energy |
| Gic Group: | Energy |
| Gic Industry: | Oil, Gas & Consumable Fuels |
| Gic Sub Industry: | Coal & Consumable Fuels |
| Description: | Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which current therapy is lacking or in need of improvement. Its products under development that are in Phase II clinical trials include RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouchitis; and RNX-051 for the treatment of colorectal cancer and colon adenoma. The company was incorporated in 2002 and is based in Hørsholm, Denmark. |
| Address: | Slotsmarken 18, 2. th., Hørsholm, Denmark, 2970 |
| Website: | https://www.pharmaequitygroup.com |
| Updated On: | 2024-11-05 |
Highlights
| Market Capitalization: | 200702784 |
| Market Capitalization Mln: | 200.70 |
| EBITDA: | -28919000 |
| Book Value: | 0.02 |
| Earnings Share: | -0.02 |
| Most Recent Quarter: | 2024-06-30 |
| Return On Assets TTM: | -0.22 |
| Return On Equity TTM: | -0.75 |
| Diluted Eps TTM: | -0.02 |
Valuation
| Price Book MRQ: | 7.72 |
| Enterprise Value: | 243105335 |
| Enterprise Value Ebitda: | 5.32 |
Shares
| Shares Outstanding: | 1227539968 |
| Shares Float: | 690173273 |
| Percent Insiders: | 1.14 |
| Percent Institutions: | 0.13 |
Technicals
| 52 Week High: | 0.5 |
| 52 Week Low: | 0.16 |
| 50 Day MA: | 0.22 |
| 200 Day MA: | 0.27 |
Splits & Dividends
| Last Split Factor: | 0.1:1 |
| Last Split Date: | 2019-10-29 |
Earnings
| Report Date: | 2023-06-30 |
| Date: | 2023-06-30 |
| Eps Actual: | -0.00 |
| Report Date: | 2023-03-31 |
| Date: | 2023-03-31 |
| Eps Actual: | -0.15 |
| Date: | 2025-12-31 |
| Period: | +1y |
| Growth: | 0.50 |
| Earnings Estimate Avg: | -0.01 |
| Earnings Estimate Low: | -0.01 |
| Earnings Estimate High: | -0.01 |
| Earnings Estimate Year Ago Eps: | -0.02 |
| Earnings Estimate Number Of Analysts: | 1.00 |
| Earnings Estimate Growth: | 0.50 |
| Revenue Estimate Avg: | 25000000.00 |
| Revenue Estimate Low: | 25000000.00 |
| Revenue Estimate High: | 25000000.00 |
| Revenue Estimate Number Of Analysts: | 1.00 |
| Eps Trend Current: | -0.01 |
| Eps Trend7days Ago: | -0.01 |
| Date: | 2024-12-31 |
| Earnings Estimate Avg: | -0.02 |
| Earnings Estimate Low: | -0.02 |
| Earnings Estimate High: | -0.02 |
| Earnings Estimate Number Of Analysts: | 1.00 |
| Revenue Estimate Number Of Analysts: | 1.00 |
| Eps Trend Current: | -0.02 |
| Eps Trend7days Ago: | -0.02 |
| Date: | 2024-09-30 |
| Period: | +1q |
| Earnings Estimate Number Of Analysts: | 1.00 |
| Revenue Estimate Number Of Analysts: | 1.00 |
| Date: | 2024-06-30 |
| Earnings Estimate Number Of Analysts: | 1.00 |
| Revenue Estimate Number Of Analysts: | 1.00 |
| Date: | 2023-06-30 |
| Eps Actual: | -0.15 |